Conference Correspondent  - Conference Correspondent, ASH
Beth Faiman, PhD, APRN-BC, AOCN
Founding Editor in Chief

Beth Faiman expresses her excitement about the newly approved multiple myeloma treatments but believes that they will also bring about new challenges.

I am thrilled that all these new drugs have been approved in 2015. We have three new drugs within the last 10 days. I cannot underscore the importance of this is for our patients and the clinicians.

This will provide a whole host of new challenges, however, with educating the nurses, and how to get the drugs, educating the patients as to how to take the drugs, and getting the drugs to the patients. Meaning, if I write a prescription, how hard is it for them to actually get that prescription filled.

Related Items
Polatuzumab Vedotin plus R-CHP Outperforms Standard of Care in Treatment of DLBCL
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in ASH
Time-Limited Venetoclax-Based Regimens Demonstrate Promising Efficacy in Fit Patients with CLL
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in ASH
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
William King
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in ASH
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
William King
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in ASH
CAR T-Cell Therapies Show Efficacy in Second-Line Treatment of Large B-Cell Lymphoma
William King
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in ASH
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Last modified: July 22, 2021